Global Blood Therapeutics (NASDAQ:GBT) Downgraded by William Blair
Global Blood Therapeutics (NASDAQ:GBT) Downgraded by William Blair
William Blair cut shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) from an outperform rating to a market perform rating in a report issued on Monday, MarketBeat reports. William Blair also issued estimates for Global Blood Therapeutics' Q3 2022 earnings at ($1.26) EPS, Q4 2022 earnings at ($1.21) EPS, FY2022 earnings at ($4.98) EPS, Q1 2023 earnings at ($1.14) EPS, Q2 2023 earnings at ($1.09) EPS, Q3 2023 earnings at ($1.03) EPS, Q4 2023 earnings at ($0.96) EPS and FY2023 earnings at ($4.22) EPS.
據MarketBeat報道，威廉·布萊爾在週一發佈的一份報告中將全球血液治療公司(納斯達克：GBT-GET評級)的股票從表現優於市場的評級下調至市場表現評級。威廉·布萊爾還發布了對全球血液治療公司2022年第三季度每股收益(1.26美元)、2022年第四季度每股收益(1.21美元)、2022年第一季度每股收益(4.98美元)、2023年第一季度每股收益(1.14美元)、2023年第二季度每股收益(1.09美元)、2023年第三季度每股收益(1.03美元)、2023年第四季度每股收益(0.96美元)和2023財年每股收益(4.22美元)的預期。
GBT has been the subject of a number of other reports. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a hold rating to a buy rating and lifted their target price for the company from $40.00 to $72.00 in a research note on Monday. Oppenheimer reduced their target price on shares of Global Blood Therapeutics from $86.00 to $71.00 in a research note on Thursday, May 5th. JPMorgan Chase & Co. reduced their price objective on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a neutral rating for the company in a research note on Tuesday, June 28th. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a hold rating to a buy rating and boosted their price objective for the stock from $40.00 to $72.00 in a research note on Monday. Finally, StockNews.com upgraded shares of Global Blood Therapeutics from a sell rating to a hold rating in a research note on Thursday, May 5th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Global Blood Therapeutics currently has a consensus rating of Hold and an average target price of $65.04.
GBT一直是其他一些報告的主題。週一，Canaccel Genuity Group在一份研究報告中將全球血液治療公司的股票評級從持有評級上調為買入評級，並將該公司的目標價從40.00美元上調至72.00美元。奧本海默在5月5日星期四的一份研究報告中將全球血液治療公司的股票目標價從86.00美元下調至71.00美元。摩根大通在6月28日星期二的一份研究報告中將全球血液治療公司的股票目標價從39.00美元下調至36.00美元，併為該公司設定了中性評級。週一，Canaccel Genuity Group在一份研究報告中將全球血液治療公司的股票評級從持有評級上調為買入評級，並將其股票目標價從40.00美元上調至72.00美元。最後，StockNews.com在5月5日星期四的一份研究報告中將全球血液治療公司的股票評級從賣出評級上調為持有評級。10名研究分析師對該股的評級為持有，6名分析師對該公司股票的評級為買入。根據MarketBeat的數據，全球血液治療公司目前的共識評級為持有，平均目標價為65.04美元。
Global Blood Therapeutics Stock Performance
全球血液治療公司股票表現
GBT stock opened at $66.57 on Monday. The company has a debt-to-equity ratio of 4.92, a quick ratio of 7.74 and a current ratio of 6.88. The stock has a market cap of $4.33 billion, a P/E ratio of -13.29 and a beta of 0.83. The firm has a 50 day simple moving average of $34.55 and a 200 day simple moving average of $31.84. Global Blood Therapeutics has a 52 week low of $21.65 and a 52 week high of $73.02.
GBT股票週一開盤報66.57美元。該公司的負債權益比率為4.92，速動比率為7.74，流動比率為6.88。該股市值為43.3億美元，市盈率為-13.29，貝塔係數為0.83。該公司的50日簡單移動均線切入位為34.55美元，200日簡單移動均線切入位為31.84美元。全球血液治療公司的52周低點為21.65美元，52周高點為73.02美元。
Insider Buying and Selling
內幕買賣
In related news, Director Philip A. Pizzo sold 1,260 shares of the business's stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total transaction of $34,335.00. Following the transaction, the director now owns 9,112 shares of the company's stock, valued at $248,302. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.90% of the stock is currently owned by insiders.
在相關新聞中，董事菲利普·A·皮佐在6月21日(星期二)的一次交易中出售了1260股該公司的股票。這些股票以27.25美元的平均價格出售，總成交額為34,335.00美元。交易完成後，董事現在持有該公司9,112股股票，價值248,302美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份法律文件中披露的，該文件可通過以下超級鏈接獲得。4.90%的股份目前由內部人士持有。
Institutional Investors Weigh In On Global Blood Therapeutics
機構投資者參與全球血液治療
Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its holdings in Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after buying an additional 650 shares during the period. ProShare Advisors LLC boosted its stake in shares of Global Blood Therapeutics by 7.6% in the 4th quarter. ProShare Advisors LLC now owns 22,609 shares of the company's stock valued at $662,000 after purchasing an additional 1,603 shares in the last quarter. Toronto Dominion Bank acquired a new stake in shares of Global Blood Therapeutics in the 4th quarter valued at $3,015,000. Vestmark Advisory Solutions Inc. boosted its stake in shares of Global Blood Therapeutics by 44.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company's stock valued at $439,000 after purchasing an additional 3,892 shares in the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Global Blood Therapeutics in the 4th quarter valued at $577,000.
機構投資者和對衝基金最近買賣了該公司的股票。NISA Investment Advisors LLC在第一季度增持了75.6%的全球血液治療公司的股份。NISA Investment Advisors LLC現在持有1,510股該公司股票，價值52,000美元，在此期間又購買了650股。ProShare Advisors LLC在第四季度將其在全球血液治療公司的股份增加了7.6%。ProShare Advisors LLC現在擁有22,609股該公司股票，價值662,000美元，上個季度又購買了1,603股。多倫多道明銀行在第四季度收購了全球血液治療公司的新股份，價值301.5萬美元。Vestmark Consulting Solutions Inc.在第一季度增持了全球血液治療公司的股份44.3%。Vestmark Consulting Solutions Inc.現在持有12,669股該公司股票，價值43.9萬美元，該公司在上個季度又購買了3,892股。最後，First Trust Advisors LP在第四季度收購了全球血液治療公司的新股份，價值57.7萬美元。
About Global Blood Therapeutics
關於全球血液治療公司
(Get Rating)
(獲取評級)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治療公司是一家生物製藥公司，致力於發現、開發和提供針對服務不足的鐮狀細胞疾病(SCD)患者羣體的治療方法。該公司提供Oxbryta片劑，這是一種治療SCD的口服藥物，每天一次。它還在第二階段對青少年和兒童SCD患者的臨牀試驗中評估了單劑和多劑Oxbryta的安全性和藥代動力學。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免費獲取StockNews.com關於全球血液治療(GBT)的研究報告
- 霍尼韋爾看好穩定和多元化的股票
- 為什麼要投資高收益股利股票？
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
- 清潔能源法案通過後，太陽能股大放異彩
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對全球血液治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。